• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HOOKIPA Pharma Inc. - Common Stock (NQ:HOOK)

0.8403 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about HOOKIPA Pharma Inc. - Common Stock

< Previous 1 2 3 Next >
News headline image
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
February 03, 2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
October 31, 2025
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
July 18, 2025
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV
January 30, 2025
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements
January 07, 2025
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Reports Third Quarter 2024 Financial Results and Provides Recent Business Updates
November 14, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma’s Eseba-vec Highlighted in SITC Late-Breaker
November 11, 2024
Phase 2 trial evaluating eseba-vec/pembrolizumab combination resulted in a 52% ORR in PD-L1 CPS>20 patients and encouraging PFS and OS data, supported by highly durable and tumor-specific T cell... 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Present Eseba-vec Combo in Frontline HNSCC as a Late-Breaker Poster Presentation at SITC 2024
October 31, 2024
Society of Immunotherapy of Cancer (SITC) poster to be presented by collaborator from Memorial Sloan Kettering Cancer Center, Dr. Alan Ho, on November 9, 2024 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Doses First Patients with Eseba-vec as Adjuvant Therapy in Phase 2 Investigator Lead Trial for Head & Neck Cancer
October 30, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Present Strong Preclinical HB-700 Dataset
September 24, 2024
Preclinical proof-of-concept package to be presented at Industry Summit on RAS being held September 24-26, 2024 
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
Kaskela Law LLC Announces Shareholder Investigation of HOOKIPA Pharma Inc. (NASDAQ: HOOK) and Encourages Investors to Contact the Firm
September 17, 2024
From Kaskela Law LLC
Via Business Wire
News headline image
HOOKIPA Pharma Announces Board of Directors Changes
August 30, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 08, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200
July 22, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Effective Date of 1-for-10 Reverse Stock Split
July 08, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment of HIV
July 01, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Updated Phase 2 Clinical Data at the American Society of Clinical Oncology 2024 Annual Meeting
June 04, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Host Investor Call on HB-200 Data Presented at American Society of Clinical Oncology 2024 Annual Meeting
May 30, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Positive Clinical Data to be Presented at the American Society for Clinical Oncology 2024 Annual Meeting
May 23, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
May 09, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
April 26, 2024
Via AB Newswire
Topics Artificial Intelligence
News headline image
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
April 25, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
April 24, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 16, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
April 10, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
March 22, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
March 06, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
January 29, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
January 16, 2024
From HOOKIPA Pharma Inc.
Via GlobeNewswire
News headline image
HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023
From HOOKIPA Pharma Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap